Key facts
- This page summarizes Eric Lefebvre's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Oct 2022, 21:05.
Eric Lefebvre - 25 Oct 2022 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- PLRX
- Reported as of
- 25 Oct 2022
- Net transaction value
- -$125,241
- SEC form
- 4
- Accepted by SEC
- 27 Oct 2022, 21:05:04 UTC
- Prior SEC filing
- 13 Jul 2022
- Next SEC filing
- 21 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mike Ouimette, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Lefebvre filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 27 Oct 2022.
Change
- Previous filing in this sequence was filed on 13 Jul 2022.
- Current net transaction value: -$125,241.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLRX
transaction
Common Stock
Sale
- Transaction value
- $125,241
- Shares
- -5,000
- Change %
- -3.6%
- Price
- $25.05
- Shares after
- 133,437
- Date
- 25 Oct 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2021.
Footnote F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.27, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Footnote F3
Includes 1 share of Common Stock acquired by the reporting person pursuant to an employee stock purchase program.